CASI Pharmaceuticals (CASIF) Return on Equity (2024)
CASI Pharmaceuticals (CASIF) reported Return on Equity of 0.0% for Q2 2024, up 99.58% quarter-over-quarter from 0.0% in Q1 2024.
CASI Pharmaceuticals (CASIF) Return on Equity (2024) Analysis & Trends
CASI Pharmaceuticals has reported Return on Equity for 1 years, with the latest figure at 0.0% in Q2 2024.
- For the quarter ending Q2 2024, Return on Equity changed N/A year-over-year to 0.0%; the trailing twelve-month figure through Jun 2024 stood at 0.0% (changed N/A YoY), and the FY2025 full-year result was 0.03%, up 3.0% from the prior year.
- Return on Equity for Q2 2024 stood at 0.0%, up from 0.0% in the prior quarter.
- The five-year high for Return on Equity was 0.0% in Q2 2024, with the low at 0.0% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | -0.81% |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | -0.04% |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | -0.01% |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | -0.01% |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |